Advances in promoting chimeric antigen receptor  T cell trafficking and infiltration of solid tumors

Curr Opin Biotechnol. 2023 Nov 15;84:103020. doi: 10.1016/j.copbio.2023.103020. Online ahead of print.ABSTRACTT cells engineered to express chimeric antigen receptors (CARs) have demonstrated robust response rates in treating hematological malignancies. However, solid tumors present multiple challenges that hinder the antitumor efficacy of CAR-T cells, including antigen heterogeneity, off-tumor and systemic toxicities, and the immunosuppressive milieu of the tumor microenvironment (TME). Notably, the TME of solid tumors is characterized by chemokine dysregulation and a dense architecture consisting of tumor stroma, extracellular matrix, and aberrant vasculature that impede migration of CAR-T cells to the tumor site as well as infiltration into the solid-tumor mass. In this review, we highlight recent advances to improve CAR-T-cell trafficking to and infiltration of solid tumors to promote effective antigen recognition by CAR-T cells.PMID:37976958 | DOI:10.1016/j.copbio.2023.103020
Source: Current Opinion in Biotechnology - Category: Biotechnology Authors: Source Type: research